TRex Bio Inc, an early-stage biotech focused on autoimmune and inflammatory diseases, raised $116.7 mln in a U.S. IPO, pricing at the low end of its proposed range.

2026-10-09

TRex Bio Inc, an early-stage biotech focused on autoimmune and inflammatory diseases, raised $116.7 mln in a U.S. IPO, pricing at the low end of its proposed range.